Generics
The generics of the quality medicines with expired patents are qualitatively equal and at the same time are up to 70 % cheaper than the original medicines. Generics represent the innovative further development of tried and tested medicines and make an annual savings contribution of 1 billion francs.
Biosimilars
Biosimilars are imitation products of biopharmaceuticals and are structurally identical to the molecule of the original manufacturer to the extent that there are no differences in effect. With their increasing spread, savings of a three-digit million sum are realistic also in Switzerland.
Spring Academy, April 2022
Experts take a stand on the “security of supply” challenge
Current topics
«Referenzpreise würden akute Lieferengpässe verschärfen» Beitrag im Amedis-Journal 3/2018
Unter der Leitung von Dr. Axel Müller, Schirmherr der Allianz “Nein zu Referenzpreisen bei Medikamenten” erfahren die Referenzpreis-Pläne des Bundesrats einen massiven und konzertierten Widerstand seitens der wichtigsten Akteure des Schweizerischen Gesundheitssystems
«Direct and indirect savings together represent a savings contribution by generics of 1billion Swiss francs per year.»
Dr. Lucas Schalch, Managing Director
«Generics must be promoted in a targeted manner to exploit their savings potential.»
«Generics enjoy a high reputation and satisfaction among Swiss patients.»
«78 percent of Swiss people are against reference prices for generics.»
«Biosimilars are of equal value to the original product.»
«Swiss generics companies are creating highly qualified jobs in this country.»
“The Corona crisis has impressively shown how important generics are for the basic supply of medicines to the Swiss population.”
Members
